Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference

Author's Avatar
Apr 18, 2023

PHILADELPHIA, PA / ACCESSWIRE / April 18, 2023 / Context Therapeutics Inc.(NASDAQ:CNTX) is a biopharmaceutical company committed to advancing medicines for solid tumors by harnessing novel and innovative treatment targets such as Claudin 6 (CLDN6).